VISEN Pharmaceuticals (VISEN) has convened an extraordinary general meeting (EGM) for 10:00 a.m. on 22 Apr 2026 at Room 1701, 1788 Square, West Nanjing Road, Jing’an District, Shanghai. Shareholders will vote by poll on three ordinary resolutions aimed at formalising and updating a series of continuing connected transactions with Ascendis-related entities.

Resolution 1 seeks approval, confirmation and ratification of the Exclusive Licence Framework Agreement signed on 26 Mar 2026 between VISEN and the ELA Ascendis Subsidiaries. The vote will also endorse a revised 2026 annual transaction cap and set future annual caps for the licence arrangement.

Resolution 2 covers the 1st Commercial Supply Framework Agreement between VISEN HK and Ascendis Pharma Endocrinology Division, also executed on 26 Mar 2026. Shareholders are asked to approve a revised 2026 commercial supply annual cap together with future caps.

Resolution 3 pertains to a supplemental agreement to the 2nd Commercial Supply Framework Agreement between VISEN HK and Ascendis Europe, including revised annual caps for forthcoming periods.

Administrative details: • Shareholders recorded as of 22 Apr 2026 are entitled to attend and vote. • The register of members will be closed from 17 Apr 2026 to 22 Apr 2026 (both dates inclusive). • Proxy forms must reach Computershare Hong Kong Investor Services by 10:00 a.m. on 20 Apr 2026. • Each share carries one vote; treasury shares, if any, have no voting rights. • In the event of Typhoon Signal No. 8, extreme conditions or a Black Rainstorm Warning within three hours of the meeting time, the EGM will be postponed, with a new schedule to be announced on HKEXnews and the company website.

As of the notice date (26 Mar 2026), VISEN’s board comprises one executive director (Mr Lu An-Bang), two non-executive directors and four independent non-executive directors.